GLOBUS MEDICAL INC 8-K

What Happened
Globus Medical, Inc. announced that at its June 3, 2026 Annual Meeting stockholders approved an amendment to the 2021 Equity Incentive Plan that increases authorized shares by 1,000,000, bringing the total to 12,000,000 shares of Class A Common Stock. The amendment became effective on June 3, 2026. At the meeting the company also elected two Class II directors, ratified Deloitte & Touche LLP as its independent auditor for 2026, and received a non-binding advisory approval of 2025 executive compensation.

Key Details

• Equity plan amendment: authorized shares under the 2021 Equity Incentive Plan increased from 11,000,000 to 12,000,000 (1,000,000 additional shares); effective June 3, 2026.
• Director elections: Keith W. Pfeil elected (For: 293,453,432; Withhold: 28,120,775; Broker non-vote: 6,902,949); Robert A. Douglas elected (For: 311,683,904; Withhold: 9,890,303; Broker non-vote: 6,902,949).
• Auditor ratification: Deloitte & Touche LLP ratified (For: 327,965,803; Against: 467,955; Abstain: 43,398).
• Say-on-pay (non-binding): 2025 executive compensation approved (For: 316,289,675; Against: 5,212,943; Abstain: 71,589; Broker non-vote: 6,902,949).

Why It Matters
Approving the additional 1,000,000 shares increases the pool available for equity awards to employees and executives, which can affect future dilution and compensation expense. The re-election of board members and ratification of the auditor reflect continuity in governance and oversight. The strong, non-binding shareholder approval of executive pay indicates investor support for the company’s compensation approach for 2025.